Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan

201883 citationsJournal Articlehybrid Open Access

Authors

Masashi Mizuguchi · The University of Tokyo

Hiroko Ikeda · National Epilepsy Center

Kuriko Kagitani‐Shimono · Osaka University

Harumi Yoshinaga · Okayama Medical Center

Yasuhiro Suzuki · Osaka Women's and Children's Hospital

Makoto Aoki · Novartis (Japan)

Masae Endo ·

Abstract

Adjunctive everolimus treatment improved seizure frequency with a tolerable safety relative to placebo among 35 Japanese patients with TSC-associated refractory seizures, consistent with the results of overall EXIST-3 study involving 366 patients. A favorable trend towards the improvement of ASD symptoms was observed.

Topics & Keywords

Tuberous Sclerosis Complex Research Polyomavirus and related diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Brain and Development

Volume 41, Issue 1, pp. 1-10

DOI: 10.1016/j.braindev.2018.07.003

Field-Weighted Citation Impact: 6.14